Early Detection Shapes Outcomes in Post-Transplant Lung Cancer

For some lung transplant recipients, the years gained after surgery bring an unexpected diagnosis: lung cancer. To shed light on this complication, a large French retrospective study of more than 7,000 lung transplant recipients from multiple treatment centers offers one of the most detailed examinations to date of lung cancer arising in this setting, tracing how detection patterns and treatment choices shape survival across stages.

A Rare but High-Stakes Complication

Lung cancer following transplantation remains uncommon, affecting 143, or 2%, of recipients in this cohort, but its clinical impact is disproportionate. The median time to diagnosis was 5.3 years, placing onset within the period when transplant recipients begin to accumulate long-term complications. Patients who developed cancer were older, more likely to have smoked, and more frequently received single-lung transplants. Donor smoking exposure also differed, suggesting a dual contribution of recipient and donor risk factors under sustained immunosuppression.

Tumor Distribution and Stage at Diagnosis

The stage distribution at diagnosis revealed a polarized pattern. 37% of cases were identified at stage I, while 35% were metastatic at presentation. This split reflects both surveillance variability and the aggressive clinical trajectory that can emerge in immunocompromised patients.

Anatomical context influenced where tumors developed. Among single-lung transplant recipients, 84% of cancers arose in the native lung, reinforcing the residual risk carried by non-transplanted tissue. Histologically, adenocarcinoma and squamous cell carcinoma predominated, aligning with broader epidemiologic patterns while occurring in a distinct host environment shaped by immunosuppression.

Surgical Resection and Survival Outcomes

Curative-intent surgery was performed in 60 patients, representing 42% of the cohort. Lobectomy was the most common procedure, and complete (R0) resection was achieved in 93% of cases where data were available. Median survival after surgical management reached 65 months, with nearly half of patients alive at last follow-up.

Operative risk was procedure-dependent. 90-day mortality was 5% following lobectomy and rose to 33% after pneumonectomy, indicating that more extensive resections carry substantial risk in this population. Postoperative complications were frequent, particularly pneumonia and pleural effusion, consistent with baseline pulmonary vulnerability and immunosuppressive exposure.

These findings support a role for lung-sparing resections when feasible, where complete tumor removal can be achieved with acceptable perioperative risk and meaningful long-term survival.

Radiotherapy as an Alternative Strategy

Radiotherapy was used with curative intent in 22% of patients, often in those not suitable for surgery. Median survival in this group was 14 months, reflecting differences in patient selection and disease burden.

Toxicity was common, with more than half of patients developing radiation-induced lung injury, though severe grade 3 or 4 events were infrequent. Corticosteroid escalation was often required, and lung function decline was observed in many cases. Differentiating treatment-related injury from chronic allograft dysfunction remained challenging, particularly when spirometric decline occurred after therapy. Radiotherapy remains a viable local option, particularly when surgical risk is prohibitive.

Systemic Therapy Constraints and Immunosuppression

Systemic therapy options were limited. Chemotherapy was administered in 43% of patients and targeted therapy in 9%, while immunotherapy was used in only a single case. The restricted use of checkpoint inhibitors reflects the ongoing risk of precipitating graft rejection.

Immunosuppressive regimens were frequently modified after cancer diagnosis. Most patients underwent reduction or discontinuation of calcineurin inhibitors, and mTOR inhibitors were introduced in approximately one-third of cases. This shift reflects an attempt to balance oncologic control with graft preservation, though standardized approaches remain undefined.

Stage-Dependent Survival and the Role of Screening

Survival outcomes varied dramatically by stage. Median overall survival reached 83 months for stage I disease but sharply declined to 16 months for stage II disease. Cancer accounted for the majority of deaths.

Screening practices varied across centers, and the data suggest that earlier detection directly influences the feasibility of curative treatment. Routine low-dose computed tomography, particularly in single-lung recipients and long-term survivors, emerges as a practical approach to shift diagnosis toward earlier stages. The observed survival gradient aligns closely with detection timing, anchoring surveillance as a central determinant of outcome.

Reference:
Saing S, El Husseini K, Picard C, et al. Lung cancer after lung transplantation: early detection and curative surgery drive long-term survival. J Heart Lung Transplant. 2026;45(4):580-588. doi:10.1016/j.healun.2025.12.001